Researchers will also be working on ultra-long-acting GLP-one analogs that could involve dosing only once per month as well as much less regularly. These prolonged-release versions could help it become even much easier to persist with using GLP-1s.  A elementary need for that approval of a generic peptide injection products would be the demonstra